Details

Autor(en) / Beteiligte

• Thordardottir, Steinunn
• Kinhult Ståhlbom, Anne
• Almkvist, Ove
• Thonberg, Håkan
• Eriksdotter, Maria
• Zetterberg, Henrik
• Blennow, Kaj
• Graff, Caroline

Titel

The effects of different familial Alzheimer's disease mutations on APP processing in vivo

Ist Teil von

• Alzheimer's research & therapy, 2017-02, Vol.9 (1), p.9-9, Article 9

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individuals carrying FAD mutations can give valuable insights into the earliest stages of the disease where therapeutic interventions are thought to be the most effective. In the current cross-sectional study, products of APP processing (e.g., sAPPα, sAPPβ, Aβ , Aβ and Aβ ) were measured in the cerebrospinal fluid (CSF) of individuals carrying one of three FAD mutations, APPswe (p.KM670/671NL), APParc (p.E693G) and PSEN1 (p.H163Y), as well as in non-mutation carriers from the same families. We observed pathological APP processing in presymptomatic carriers of FAD mutations, with different profiles of APP and Aβ isoforms in the three mutation carrier groups, APPswe (p.KM670/671NL), APParc (p.E693G) and PSEN1 (p.H163Y), except for the well-established decrease in CSF Aβ that was found with all mutations. These findings add to the current evidence that AD pathophysiology differs between disease-causing mutations and can be monitored in the presymptomatic disease stage by CSF analyses. This may also be important from a therapeutic standpoint, by opening a window to monitor effects of disease-modifying drugs on AD pathophysiology.